

## **Christos Kyratsous, PhD**

Vice President – Research

Infectious Diseases and Viral Vector Technologies

Regeneron Pharmaceuticals, Inc.

christos.kyratsous@regeneron.com

Christos Kyratsous holds a PhD in Microbiology from Columbia University, College of Physicians and Surgeons. He joined Regeneron in 2011 and is now Vice President for Research, heading the pre-clinical Infectious Diseases research group and a technology development group focused on viral vector engineering. In his role, he oversees a diverse portfolio of anti-pathogen fully-human monoclonal antibodies and novel gene and cell therapies. His group's projects include antibodies developed as part of Regeneron's Rapid Response against emerging viruses, e.g. the antibodies against Ebola virus, which is the first FDA approved therapy against this disease, and antibodies against SARS-CoV-2, which were recently authorized by FDA for emergency use during the COVID19 pandemic.